Emergent BioSolutions (NYSE: EBS) reported Q1 EPS of $0.18, $0.06 better than the analyst estimate of $0.12. Revenue for the quarter came in at $307.5 million versus the consensus estimate of $283.57 million.

For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.